| TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck (NCT03729518) | Abramson Cancer Center at Penn Medicine | 2018-10-11 |
| Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies (NCT03680677) | Abramson Cancer Center at Penn Medicine | 2018-09-21 |
| A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer (NCT03616522) | Abramson Cancer Center at Penn Medicine | 2018-05-21 |
| Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment (NCT03573986) | Abramson Cancer Center at Penn Medicine | 2018-04-18 |
| In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer (NCT03492164) | Abramson Cancer Center at Penn Medicine | 2018-03-20 |
| Avelumab/Gemcitabine in Sarcomatoid RCC (NCT03483883) | Abramson Cancer Center at Penn Medicine | 2018-03-19 |
| Personalized Radiation Therapy for GBM (NCT03477513) | Abramson Cancer Center at Penn Medicine | 2018-03-01 |
| Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy (NCT03535987) | Abramson Cancer Center at Penn Medicine | 2018-01-19 |
| Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model (NCT03934606) | Abramson Cancer Center at Penn Medicine | 2018-01-01 |
| Genetics and Heart Health After Cancer Therapy (NCT03510689) | Abramson Cancer Center at Penn Medicine | 2017-12-05 |
| Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer (NCT03087760) | Abramson Cancer Center at Penn Medicine | 2017-11-29 |
| To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer (NCT03215264) | Abramson Cancer Center at Penn Medicine | 2017-10-02 |
| A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer (NCT03300921) | Abramson Cancer Center at Penn Medicine | 2017-09-28 |
| Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy (NCT03140670) | Abramson Cancer Center at Penn Medicine | 2017-09-05 |
| Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer (NCT03334500) | Abramson Cancer Center at Penn Medicine | 2017-07-14 |
| Circulating Tumor Material in Colorectal Cancer and Melanoma (NCT02907086) | Abramson Cancer Center at Penn Medicine | 2017-07-07 |
| Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma (NCT03173430) | Abramson Cancer Center at Penn Medicine | 2017-05-27 |
| A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION (NCT03155672) | Abramson Cancer Center at Penn Medicine | 2017-05-15 |
| RCT of ACP for Transplant (NCT03158467) | Abramson Cancer Center at Penn Medicine | 2017-05-15 |
| A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION (NCT03151642) | Abramson Cancer Center at Penn Medicine | 2017-04-05 |
| Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC) (NCT02906397) | Abramson Cancer Center at Penn Medicine | 2017-03-30 |
| AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors (NCT03363711) | Abramson Cancer Center at Penn Medicine | 2017-03-01 |
| Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer (NCT03083288) | Abramson Cancer Center at Penn Medicine | 2017-02-22 |
| Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide (NCT03065790) | Abramson Cancer Center at Penn Medicine | 2017-02-06 |
| A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity (NCT03427021) | Abramson Cancer Center at Penn Medicine | 2017-02-01 |
| CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer (NCT03032406) | Abramson Cancer Center at Penn Medicine | 2017-01-23 |
| A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer (NCT03047616) | Abramson Cancer Center at Penn Medicine | 2016-11-22 |
| Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain (NCT02906787) | Abramson Cancer Center at Penn Medicine | 2016-09-13 |
| RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy (NCT02880345) | Abramson Cancer Center at Penn Medicine | 2016-08-01 |
| Intraoperative Imaging With ICG Registry (NCT02640170) | Abramson Cancer Center at Penn Medicine | 2016-07-01 |
| Correlation of Early Postoperative Scar Appearance With Long-term Scar Outcomes (NCT04015453) | Abramson Cancer Center at Penn Medicine | 2016-07-01 |
| Imaging FDG Flare in Melanoma (NCT02791594) | Abramson Cancer Center at Penn Medicine | 2016-06-01 |
| Study of Efficacy and Safety of CTL019 in Adult ALL Patients (NCT02167360) | Abramson Cancer Center at Penn Medicine | 2016-06-01 |
| Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) | Abramson Cancer Center at Penn Medicine | 2016-04-06 |
| Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer (NCT03057743) | Abramson Cancer Center at Penn Medicine | 2016-04-05 |
| PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer (NCT02732171) | Abramson Cancer Center at Penn Medicine | 2016-04-01 |
| FDG PET/CT in Lung Cancer Staging (NCT02738398) | Abramson Cancer Center at Penn Medicine | 2016-04-01 |
| Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710 (NCT02756637) | Abramson Cancer Center at Penn Medicine | 2016-04-01 |
| Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology (NCT02756767) | Abramson Cancer Center at Penn Medicine | 2016-04-01 |
| C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer (NCT02715583) | Abramson Cancer Center at Penn Medicine | 2016-03-01 |
| Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (NCT02724540) | Abramson Cancer Center at Penn Medicine | 2016-03-01 |
| Early FDG PET in Melanoma (NCT02716077) | Abramson Cancer Center at Penn Medicine | 2016-03-01 |
| Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers (NCT02639026) | Abramson Cancer Center at Penn Medicine | 2016-01-26 |
| Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT (NCT02637934) | Abramson Cancer Center at Penn Medicine | 2016-01-14 |
| Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis (NCT02769546) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
| A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study (NCT02767726) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
| A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer (NCT02599363) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
| Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas (NCT02650999) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
| Optional Sub-study to Intraoperative Imaging With ICG Registry (NCT02651246) | Abramson Cancer Center at Penn Medicine | 2015-12-01 |
| Exercise and Colon Cancer (NCT02250053) | Abramson Cancer Center at Penn Medicine | 2015-12-01 |
| Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab (NCT02993536) | Abramson Cancer Center at Penn Medicine | 2015-11-01 |
| Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy (NCT02608528) | Abramson Cancer Center at Penn Medicine | 2015-10-22 |
| Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma (NCT02588443) | Abramson Cancer Center at Penn Medicine | 2015-10-01 |
| Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases (NCT02471170) | Abramson Cancer Center at Penn Medicine | 2015-09-10 |
| Gut Microbiota And Radiotherapy (NCT02559349) | Abramson Cancer Center at Penn Medicine | 2015-09-01 |
| A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services (NCT02517554) | Abramson Cancer Center at Penn Medicine | 2015-08-01 |
| Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer (NCT02665962) | Abramson Cancer Center at Penn Medicine | 2015-07-01 |
| Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy (NCT02303977) | Abramson Cancer Center at Penn Medicine | 2015-06-26 |
| Indocyanine Green for Central Nervous System Tumors (NCT02710240) | Abramson Cancer Center at Penn Medicine | 2015-06-10 |
| Cardiotoxicity of Radiation Therapy (CTRT) (NCT02769299) | Abramson Cancer Center at Penn Medicine | 2015-06-02 |
| Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity (NCT02469194) | Abramson Cancer Center at Penn Medicine | 2015-06-01 |
| WISER After Ovarian Cancer - Exercise Pilot Study (NCT02529150) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| Dietary Flaxseed in NSCLC (NCT02475330) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| Autologous OC-L Vaccine and Ovarian Cancer (NCT02452775) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk (NCT02478892) | Abramson Cancer Center at Penn Medicine | 2015-05-01 |
| A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma (NCT02434354) | Abramson Cancer Center at Penn Medicine | 2015-04-01 |
| Study on Breast Cancer Patient Perspectives of Exercise (NCT02559362) | Abramson Cancer Center at Penn Medicine | 2015-04-01 |
| Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care (NCT02558998) | Abramson Cancer Center at Penn Medicine | 2015-03-01 |
| The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer (NCT02380196) | Abramson Cancer Center at Penn Medicine | 2015-03-01 |
| A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA) (NCT02363829) | Abramson Cancer Center at Penn Medicine | 2015-02-01 |
| Clinical Utility of a Low-Cost Hand-Held Breast Scanner (NCT02762565) | Abramson Cancer Center at Penn Medicine | 2015-02-01 |
| Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer (NCT02316002) | Abramson Cancer Center at Penn Medicine | 2015-01-21 |
| RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers (NCT02303990) | Abramson Cancer Center at Penn Medicine | 2015-01-08 |
| Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient Satisfaction (NCT02559219) | Abramson Cancer Center at Penn Medicine | 2014-12-01 |
| IFN-DLI for Relapsed Acute Leukemia After Allo-SCT (NCT02331706) | Abramson Cancer Center at Penn Medicine | 2014-12-01 |
| Evaluating Therapeutic Response to Novo-TTF (NCT02441322) | Abramson Cancer Center at Penn Medicine | 2014-12-01 |
| Healthy Human Control Blood Collection for Validation of Biomarker Assay (NCT02302885) | Abramson Cancer Center at Penn Medicine | 2014-11-01 |
| Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (NCT02257424) | Abramson Cancer Center at Penn Medicine | 2014-10-01 |
| PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community Hospitals (NCT02559375) | Abramson Cancer Center at Penn Medicine | 2014-09-01 |
| A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT02277392) | Abramson Cancer Center at Penn Medicine | 2014-09-01 |
| FDG-PET/CT Imaging as Early Predictor of DP (NCT02476734) | Abramson Cancer Center at Penn Medicine | 2014-08-01 |
| Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox) (NCT02233504) | Abramson Cancer Center at Penn Medicine | 2014-08-01 |
| Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts (NCT02246738) | Abramson Cancer Center at Penn Medicine | 2014-08-01 |
| Adherence to Aromatase Inhibitors: The Role of Partners (NCT02753985) | Abramson Cancer Center at Penn Medicine | 2014-07-01 |
| Assessment of Cancer Concerns at the End of Treatment (ACE) (NCT02514486) | Abramson Cancer Center at Penn Medicine | 2014-07-01 |
| A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer (NCT02207465) | Abramson Cancer Center at Penn Medicine | 2014-07-01 |
| Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (NCT02207439) | Abramson Cancer Center at Penn Medicine | 2014-07-01 |
| Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study (NCT02514499) | Abramson Cancer Center at Penn Medicine | 2014-07-01 |
| Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (NCT02153229) | Abramson Cancer Center at Penn Medicine | 2014-06-02 |
| Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation (NCT02559401) | Abramson Cancer Center at Penn Medicine | 2014-06-01 |
| A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck. (NCT02277548) | Abramson Cancer Center at Penn Medicine | 2014-05-01 |
| Patient-Centered Acupuncture for Pain (PCAP) (NCT02152020) | Abramson Cancer Center at Penn Medicine | 2014-05-01 |
| Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer (NCT02213497) | Abramson Cancer Center at Penn Medicine | 2014-04-01 |
| Acupuncture Feasibility Trial for Dyspnea in Lung Cancer (NCT02094950) | Abramson Cancer Center at Penn Medicine | 2014-03-01 |
| Functional Outcome Measures for Head and Neck Patients (NCT02530112) | Abramson Cancer Center at Penn Medicine | 2014-02-02 |
| A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer (NCT02159703) | Abramson Cancer Center at Penn Medicine | 2014-02-01 |
| [18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers (NCT02108457) | Abramson Cancer Center at Penn Medicine | 2014-02-01 |
| A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer (NCT02030860) | Abramson Cancer Center at Penn Medicine | 2014-01-01 |
| Ablative Fractional Laser for Sclerotic GVHD-Associated Joint Contractures (NCT02881047) | Abramson Cancer Center at Penn Medicine | 2013-11-11 |
| Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma (NCT02828345) | Abramson Cancer Center at Penn Medicine | 2013-11-01 |